MOUNTAIN VIEW, Calif., July 20, 2023 /PRNewswire/ -- Lark Health, the leading AI-powered digital care coaching company for the prevention and management of chronic conditions, and Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, today announced their expanded partnership where DOHC will offer Lark's Prevention program and CDC-recognized Diabetes Prevention program to their patients.
Coming off the success of their Heart Health partnership, DOHC is making Lark's programs available to their greater patient populations for enhanced remote monitoring and scalable education programs designed to improve outcomes and lower total healthcare costs. The new program offerings will enable DOHC to target specific conditions, such as, prediabetes, diabetes, hypertension, high cholesterol and general preventive care. Additionally, patients who meet certain health-related criteria will be eligible for connected devices, providing qualified participants with deeper insights into their health through a more personalized care experience.
"Lark Health has combined technology with clinical expertise for years and been a great partner," - VP, Clinical Quality
"Desert Oasis Healthcare is a proven innovator in value-based care, and we are excited to expand our partnership to offer Lark programs to more of their patients," said Dr. Jason Paruthi, Medical Director at Lark Health. "Lark's education programs, remote patient monitoring and screeners will enable improved outcomes at lower cost for DOHC as well as comprehensive access to care for their patients."
The benefits of this partnership will give DOHC access to remote patient monitoring and screeners, allowing timely escalation to the DOHC care team; sustained patient engagement supported with proven outcomes, as well as, scalable patient education and self efficacy program.
"Lark Health has been combining technology with clinical expertise for our patients for years already and we've found them to be a great partner," said Teresa Hodgkins PharmD, BCACP and Vice President of Clinical Quality Initiatives at Desert Oasis Healthcare. "We're convinced they'll continue to be our ally and helpmate in preventing the complications that come with disease progression, and improving outcomes for our diabetes and heart disease patients."
About Lark Health
Using conversational AI, connected devices, remote patient monitoring, and elements of behavioral science techniques, Lark helps participants improve their health to manage and reduce their risk of chronic disease. Lark's scalable platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to support their chronic care prevention and management programs. Lark's Diabetes Prevention Program (DPP), the fastest-growing and lowest-cost DPP, has received Full Recognition from the CDC.
The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards (2022), one of Fast Company's Most Innovative Companies (multiple years), and one of Fierce Healthcare's Fierce 15 (2020). To learn more, visit .
Lark currently works with many of the largest health plans across five programs: Prevention, Heart Health, Diabetes Prevention, Diabetes Management, and Hypertension Management.
Formed in 1981 as one of the first medical groups in the desert communities of southern California, Desert Oasis Healthcare (DOHC) continues to advance with changes in the healthcare market. DOHC provides primary and immediate care, home health, palliative care, clinical research studies and other services to more than 60,000 members/patients living in the greater Coachella Valley and the Morongo Basin of Riverside and San Bernardino counties. The multidisciplinary and comprehensive care programs of DOHC are committed to educating individuals on preventive health care in their daily lives, reflected in the DOHC motto, "Your Health. Your Life. Our Passion." For more information, visit .
SOURCE Lark Health
California’s Desert Oasis Healthcare (DOHC) implements Rimidi’s Respiratory Module for respiratory patient monitoring, based on data collected by Teva’s Digihaler® System
Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management
Teva and Rimidi look to expand respiratory monitoring program to additional health systems with the aim of assessing potential cost savings, hospitalization rates and the quality of asthma management
PARSIPPANY, N.J.--(BUSINESS WIRE)--
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare (DOHC) system. The program was designed in collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. Teva’s Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management
The implementation of this respiratory monitoring program in a large health system is a vital step in helping to ensure patients are getting the resources they need to develop informed treatment plans with their doctors. Teva and Rimidi continue to look for ways to expand this respiratory monitoring program by partnering with additional health systems in an effort to reduce high costs, lower hospitalizations and improve asthma management.
“Teva aims to be a leader in fusing technology and healthcare in order to help patients and their doctors more easily manage their treatment plans. Through collaborations with partners like Rimidi, we hope to improve the patient continuum of care, leading to a more cost-effective healthcare system,” said Manny Montalvo, Senior Vice President, Head of Digital Health & Innovation at Teva. “More than 34 million Americans live with a chronic lung disease, and approximately 25 million people in the U.S. currently have asthma.
We’re energized by the potential of collaborations like this to drive meaningful differences in how asthma is managed and treated, with the collective vision of one day predicting asthma attacks before they occur.”
Through this collaboration, DOHC has identified patients with respiratory conditions indicated for treatment with one or more of the products in Teva’s Digihaler family of inhalers, and who are appropriate candidates for enrollment via the Rimidi platform. Data from Teva’s Digihaler System will be available through Rimidi’s Respiratory Module, which is designed to give providers a more complete view of the patient to help guide treatment decisions for those with respiratory diseases, such as chronic obstructive pulmonary disease (COPD) or asthma.
“The ability to have a streamlined, comprehensive view of a patient’s health condition allows for more efficient and personalized management,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Rimidi’s Respiratory Module incorporates clinical decision support tools to help clinicians understand potential reasons behind a patient’s uncontrolled asthma, such as not taking their medication or not taking it properly. These factors are fundamental to achieving good asthma control.”
Integrating data from the smart inhalers into the clinician’s electronic health records through the Respiratory Module can help support the management of COPD and asthma. Longer term, outcomes from DOHC’s initial patient cohort will provide valuable insights to inform the use of data from Teva’s Digihaler System and the module in U.S. health systems. The platform can be used to monitor and manage large populations by a network of health systems, capturing objective and actionable data for asthma patients. The goal is to assess how this approach can help address high costs, lower hospitalizations and improve asthma management.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at
About Teva Digital Health
Teva aims to be a global leader in personalized, predictive care, continuously investing in platforms and regulatory-compliant systems that will help change the nature of digital health as we know it. Teva’s proprietary software platform, Digihaler
– developed and maintained in-house by a team of research specialists and programmers – is built into a series of FDA-approved inhalers, currently marketed in the U.S. Learn more at
Created by doctors, Rimidi’s leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit
and follow us on Twitter and LinkedIn.
About Desert Oasis Healthcare
Formed in 1981 as one of the first medical groups in the desert communities of southern California, Desert Oasis Healthcare (DOHC) continues to advance with changes in the healthcare market. DOHC provides primary and immediate care, home health, palliative care, and other services to more than 60,000 members/patients living in the greater Coachella Valley and the Morongo Basin of Riverside and San Bernardino counties. The multidisciplinary and comprehensive care programs of DOHC are committed to educating individuals on preventative health care in their daily lives, reflected in the DOHC motto, "Your Health. Your Life. Our Passion." For more information, visit
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to the development and commercial success of our Digihaler products family; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our innovative medicines, including AUSTEDO
, our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including, the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
The American Lunch Association. Our Impact (2023).
View source version on
Ran Meir (267) 468-4475
Sanjeev Sharma (973) 524-1908
Kelley Dougherty (973) 658-0237
Yonatan Beker (973) 264-7378
Source: Teva Pharmaceutical Industries Limited
All medical groups achieve Elite status
NORTHRIDGE, Calif., Nov. 1, 2022 /PRNewswire/ -- Heritage Provider Network (HPN) one of the nations most experienced and innovative physician led value-based care organizations, and its family of medical groups achieved the highest possible scores from America's Physician Groups (APG) annual Standards of Excellence™ (SOE®) survey. All medical groups in the HPN family earned Elite Status, the top ranking in the nation. ()
America’s Physician Groups (APG)
" I'm so proud of all of our HPN team members in each medical group who have worked diligently throughout the pandemic to continue our quality, cost effective care and achieve this highest honor," said Dr. Richard Merkin, President and CEO of HPN. "I'm delighted to share this with them."
"Elite status signifies that these APG members are fully equipped with the necessary capabilities to thrive in value-based care models, and to take accountability and responsibility for the costs and quality of health care," said APG President and CEO Susan Dentzer, MS. "
The elite 5-star status is the highest possible honor awarded by the nation's leading association for physician organizations practicing coordinated care. Elite 5-star Status in all categories of the survey was achieved by all nine of HPN's family of medical groups including:
Affiliated Doctors of Orange County
Sierra Medical Group
Regal Medical Group
Lakeside Medical Group
Heritage Victor Valley Medical Group
High Desert Medical Group
Desert Oasis Healthcare
Coastal Communities Physician Network
Bakersfield Family Medical Group
APG is the country's leading organization representing physician groups practicing coordinated care. APG's Standard of Excellence™ (SOE®) Elite award for patient care includes five rigorous categories-care management practices, patient-centered care, information technology, group support of advanced primary care, accountability and transparency.
Heritage Provider Network, Inc. (HPN) is one of the most experienced physician organization leaders of accountable care and continuous value-based healthcare delivery improvements. Developing and managing coordinated, patient-doctor centric, integrated health care systems that offers some of the strongest solutions for the future of health, care and cost in the United States. HPN and its affiliates operate in New York, California, Arizona providing high-quality, cost-effective healthcare with over one million patient members and are dedicated to quality, affordable health care, and putting patients' wellness first
SOURCE Heritage Provider Network, Inc.